CVS Health Co. (NYSE:CVS) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. cut its stake in shares of CVS Health Co. (NYSE:CVS) by 7.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 187,825 shares of the pharmacy operator’s stock after selling 15,108 shares during the period. D.A. Davidson & CO.’s holdings in CVS Health were worth $8,432,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Assetmark Inc. raised its position in CVS Health by 9.7% during the third quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator’s stock worth $25,781,000 after acquiring an additional 36,132 shares during the period. TD Private Client Wealth LLC raised its position in shares of CVS Health by 28.7% in the third quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock valued at $2,951,000 after buying an additional 10,465 shares during the last quarter. Cullinan Associates Inc. raised its position in shares of CVS Health by 43.8% in the third quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator’s stock valued at $7,125,000 after buying an additional 37,395 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of CVS Health by 4.8% in the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock valued at $90,200,000 after buying an additional 66,244 shares during the last quarter. Finally, Sompo Asset Management Co. Ltd. raised its position in shares of CVS Health by 8.4% in the third quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator’s stock valued at $8,459,000 after buying an additional 10,453 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Trading Down 0.5 %

Shares of CVS stock opened at $65.47 on Wednesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The firm has a market cap of $82.39 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 0.60 and a beta of 0.61. The company has a 50-day moving average of $51.30 and a two-hundred day moving average of $56.03. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $80.75.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. On average, analysts predict that CVS Health Co. will post 5.14 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.06%. The ex-dividend date was Thursday, January 23rd. CVS Health’s payout ratio is 67.51%.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of recent research reports. Royal Bank of Canada reduced their target price on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Evercore ISI increased their target price on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Monday, January 27th. Barclays increased their target price on shares of CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Wells Fargo & Company raised their price objective on shares of CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $80.00 to $81.00 and gave the stock an “overweight” rating in a research report on Tuesday. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.00.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.